Sea Water in Allergic Conjunctivitis

Sponsor
University of Valencia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04695795
Collaborator
(none)
50
21.9

Study Details

Study Description

Brief Summary

Background and purpose: Allergic conjunctivitis has increased alarmingly in recent years. The objectives of the study are: 1) To establish the safety and efficacy of applying eyewashes in spray form as monotherapy on the symptoms and signs of allergic conjunctivitis; 2) To establish the comparative efficacy with other eye drops as antihistamines; 3) To measure the modification of immunoglobulin E (IgE) and matrix metalloproteinase 9 (MMP9) levels in the tears.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Material and methods: Prospective study. A total of 50 patients will be included. A scale from 0 to +3 will be established to quantify the intensity of the different parameters measured. A total of 8 symptoms will be studied - itching, tearing, mucous secretions, photophobia, foreign body sensation, redness, rubbing, palpebral swelling, and 3 signs - palpebral papillae, conjunctival hyperemia, and corneal involvement (dotted keratitis). Control at 30 minutes, 1 day, and 1 month after the application of the treatment. At the end of the treatment period, the degree of satisfaction with the treatment, the desire to continue or abandon it, and the need to associate other complementary treatments due to lack of control will also be evaluated. All patients will be treated exclusively with seawater isotonic solution in the form of a spray 5 times a day for 1 month. A second similar group of patients will be treated with antihistamine eye drops and a third group of patients with both antihistamine eye drops and seawater. Tears measurement of immunoglobulin E and matrix metalloproteinase 9 levels will be measured before and after treatment.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Efficacy and Safety of Seawater in Allergic Conjunctivitis. IgE and MMP-9 Tear Levels. Antihistaminic Eyedrops Comparative Study.
    Anticipated Study Start Date :
    Feb 1, 2021
    Anticipated Primary Completion Date :
    May 1, 2021
    Anticipated Study Completion Date :
    Dec 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Measure the symptoms, and corneal and conjunctival signs before and after treatment, Bonini scale [1 month]

      A scale from 0 to +3 will be established to quantify the intensity of the different parameters measured. A total of 8 symptoms will be studied - itching, tearing, mucous secretions, photophobia, foreign body sensation, redness, rubbing, palpebral swelling, and 3 signs - palpebral papillae, conjunctival hyperemia, and corneal involvement (dotted keratitis).

    2. Measure metalloproteinase 9 in tears before and after treatment [1 month]

      To administer the test, physician collects a tear sample, then activates it with a buffer solution. In 10 minutes, the test will be ready, and will either show a solitary blue line, indicating a negative result, or a blue line accompanied by a red line, which is positive.

    3. Measure immunoglobulin E in tears before and after treatment [1 month]

      A strip is placed in the lower conjunctival fornix and, when wet with tears, is removed. Signal intensity is dependent on the total Immunoglobulin E level.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    10 Years to 80 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    The inclusion criteria were patients with mild or moderate allergic conjunctivitis as detailed in Table I. The minimum to be included in the study was the presence in both eyes of three symptoms and one sign (Table II). Among the symptoms, the presence of itching and two more of the following were essential: redness, tearing, foreign body sensation, rubbing, mucous secretion, and/or palpebral swelling sensation. Among the signs, conjunctival hyperemia, papillae in the palpebral conjunctiva, and/or corneal affectation in the form of dotted keratitis were evaluated.

    Table 1 Degree of conjunctivitis I Mild II Moderate III Severe IV Blinding

    Conjunctiva bulbar: congestion granuloma Conjunctiva tarsal: micropapillae 1mm giant >1 mm cobblestone Corneal staining : micro macro shield ulcer Limbal affectation: < 180 degrees

    180 degrees insufficiency limbo/pannus/ vascularization corneal

    Table 2 Signs and symptoms evaluated initially and at each visit

    Symptoms Signs:
    • Itching - Conjunctival Hyperemia

    • Redness - Pads

    • Foreign body sensation - palpebral swelling

    • Photophobia

    • Eyelid swollen sensation

    • Mucous secretions

    • Rubbing

    • Tears

    Exclusion Criteria:
    • blepharitis

    • meibomian gland dysfunction syndrome (MGS)

    • dry eye disease

    • topical eye drug such as cyclosporine, tacrolimus, interferon-alpha, mitomycin

    • previous eye surgery

    • corneal refractive surgery.

    • use of contact lenses

    • glaucoma

    • pterygium

    • ocular pemphigoid

    • anti-allergic vaccines

    • oral or subcutaneous drugs such as antihistamines, anti-leukotrienes (montelukast), corticoids, immunosuppressants or biological drugs.

    • rhinitis and dermatitis

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Valencia

    Investigators

    • Study Chair: mariadolores pinazoduran, MD,Prof, University of Valencia, Spain

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Valencia
    ClinicalTrials.gov Identifier:
    NCT04695795
    Other Study ID Numbers:
    • 1236
    First Posted:
    Jan 5, 2021
    Last Update Posted:
    Jan 5, 2021
    Last Verified:
    Dec 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Valencia
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 5, 2021